Fig. 4From: The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human studyRM absorbed dose at the first cycle in patients with (Yes) and without (No) any haematological toxicityBack to article page